Hong Kong Stock Movement
TRANSTHERA-B rose 17.13%. Based on recent key news:
<ol>
<li>
On November 3, TRANSTHERA-B signed a patent transfer and research collaboration agreement with Neurocrine Biosciences. The agreement grants Neurocrine exclusive rights to develop, manufacture, and commercialize NLRP3 inhibitors outside of Greater China, while TRANSTHERA-B retains relevant rights in Greater China. The total potential value of the agreement is USD 881.5 million, driving the stock price up.
</li>
<li>
On November 3, TRANSTHERA-B announced its collaboration agreement with Neurocrine on the Hong Kong Stock Exchange, and the market's positive reaction to the agreement led to a more than 6% increase in the stock price at the open, continuing to rise during trading.
</li>
<li>
On November 3, TRANSTHERA-B's announcement attracted market attention, with a trading volume of HKD 6.5627 million, indicating high investor interest in the collaboration agreement. Collaborations in the innovative drug industry drove the stock price up.
</li>
</ol>
Stocks with High Trading Volume in the Industry
Kangfang Biopharma rose 2.52%. Based on recent news,
<ol>
<li>
On November 3, JP Morgan reported that mainland healthcare stocks have significantly corrected since early last month, with the Hang Seng Healthcare Index and the CSI 300 Healthcare Index falling 12% and 9% respectively this month. The bank believes that rising tensions between China and the U.S. and increased geopolitical risk premiums have prompted investors to take profits, leading to volatility in Kangfang Biopharma's stock price.
</li>
<li>
On November 2, Kangfang Biopharma announced that its innovative bispecific antibody ivonescimab received breakthrough therapy designation for the first-line treatment of triple-negative breast cancer. This news boosted market confidence and drove the stock price up.
</li>
<li>
On November 3, Soochow Securities reported that many domestic companies are actively laying out in the brain-computer interface direction, with the global medical device market continuing to develop, and domestic manufacturers expanding overseas. Kangfang Biopharma, as one of the preferred stocks, has attracted market attention. The healthcare industry is experiencing a correction, with increased geopolitical risks.
</li>
</ol>
Innovent Biologics rose 0.92%. Based on recent news,
<ol>
<li>
On November 4, Innovent Biologics recorded a block trade of 294,000 shares at a price of HKD 87.35 per share, which is 3.2% lower than the previous closing price, involving a total of HKD 25.68 million. This transaction caused short-term volatility in the stock price.
</li>
<li>
On November 3, Innovent Biologics announced the initiation of several new clinical studies, including research on obese adolescents, metabolic-associated fatty liver disease (MASH), and heart failure with preserved ejection fraction (HFpEF). These new research plans boosted market confidence.
</li>
<li>
On November 2, Innovent Biologics reached a cooperation agreement with Takeda involving an upfront payment of USD 1.2 billion, with a total scale of up to USD 11.4 billion. This cooperation agreement demonstrates Innovent Biologics' potential in the global market and further enhances investor confidence. The Hong Kong innovative drug ETF continues to see net inflows, and the market outlook is positive
Sangfor Pharmaceuticals rose by 0.87%. Based on recent key news:
</li>
<li>
On November 3rd, Sangfor Pharmaceuticals and Pfizer launched a global Phase III clinical trial for their dual-antibody drug, boosting market confidence. The drug targets non-small cell lung cancer and colorectal cancer, driving the stock price up.
</li>
<li>
On November 3rd, the Hong Kong stock market's innovative drug sector strengthened overall, with Sangfor Pharmaceuticals benefiting from the introduction of the &#34;Commercial Insurance Innovative Drug Catalog&#34; mechanism, leading to a rebound in sector sentiment and an increase in stock price.
</li>
<li>
On November 4th, funds continued to flow into Sangfor Pharmaceuticals, with the stock price 2.23% above the 50-day moving average, indicating further upward momentum. The pharmaceutical industry's sentiment is improving, with noticeable capital inflows.
</li>
</ol>
Stocks ranked among the top in industry market capitalization
BeiGene rose by 0.60%. Based on recent key news:
<ol>
<li>
On November 2nd, BeiGene participated in price negotiations for the Commercial Insurance Innovative Drug Catalog, bringing multiple drugs to the table, including injectable zanidatamab, demonstrating its proactive positioning in the innovative drug field, which drove the stock price up. Source: Economic Observer
</li>
<li>
On November 3rd, the trend of Chinese innovative drugs &#34;going global&#34; is positive, with BeiGene as one of the partners involved in multiple international cooperation agreements, enhancing its international market position and supporting the rise in stock price. Source: Securities Daily
</li>
<li>
On November 5th, the innovative drug ETF saw active trading, with BeiGene as one of the constituent stocks benefiting from the market's positive expectations for the innovative drug industry, leading to an increase in stock price. Source: Huafu Securities analysis indicates a rise in the international status of innovative drugs and noticeable capital inflows
</li>
</ol>

02617

TRANSTHERA-B rose 17.13%; CanSino Biologics rose 2.52%, with a transaction volume of HKD 1.003 billion; Innovent Biologics rose 0.92%, with a transaction volume of HKD 792 million; 3SBio rose 0.87%, with a transaction volume of HKD 600 million; BeiGene rose 0.60%, with a market capitalization of HKD 284.9 billion

Hong Kong Stock Movement: TRANSTHERA-B rises 17.13%, $881.5 million cooperation agreement ignites market enthusiasm